Postmortem findings and clinical correlates in individuals with infantile-Onset pompe disease

JIMD Reports

Volumn 23, Issue , 2015, Pages 45-54

  Pena, Loren D M ^a   Proia, Alan D ^a   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acid alpha glucosidase deficiency; Autopsy; Cardiomyopathy; Glycogen storage disorder; Lysosomal storage disorder; Pompe disease

Indexed keywords

EID: 84994426877     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2015_426     Document Type: Chapter

References (37)

1. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB et al (2003) Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff–Parkinson–White syndrome in glycogen storage cardiomyopathy. Circulation 107:2850–2856
2. Araoz C, Sun CN, Shenefelt R, White HJ (1974) Glycogenosis type II (Pompe’s disease): ultrastructure of peripheral nerves. Neurology 24:739–742
3. Asukata I, Aizawa S, Kosakai M, Kirino Y, Ishikawa E (1976) An autopsy case of type II glycogenosis. Acta Path Jpn 26:629–635
4. Austin SL, Proia AD, Spencer-Manzon MJ, Butany J, Wechsler SB, Kishnani PS (2012) Cardiac pathology in glycogen storage disease type III. JIMD Rep 31:65–72
5. Bernstein DL, Bialer MG, Mehta L, Desnick RJ (2010) Pome disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab 101:130–133
6. Bharati S, Serratto M, DuBrow I et al (1982) The conduction system in Pompe’s disease. Pediatr Cardiol 2:25–32
7. Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ (2010) Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol 42:455–458
8. Chien YH, Lee NC, Peng SF, Hwu WL (2006) Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res 60:349–352
9. Dubrovsky A, Corderi J, Lin M, Kishnani PS, Jones HN (2011) Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation. Muscle Nerve 44:897–901
10. El-Gharbawy AH, Bhat G, Murillo JE et al (2011) Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. Mol Genet Metab 103:362–366
11. Fidziańska A, Ługowska A, Tylki-Szymańska A (2011) Late form of Pompe disease with glycogen storage in peripheral nerves axons. J Neurol Sci 301:59–62
12. Hobson-Webb LD, Proia AD, Thurberg BL, Banugaria S, Prater SN, Kishnani PS (2012) Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genet Metab 106:462–469
13. Jones HN, Muller CW, Lin M et al (2010) Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia 25:277–283
14. Kishnani PS, Nicolino M, Voit T et al (2006) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149:89–97
15. Laforêt P, Petiot P, Nicolino M et al (2008) Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology 70:2063–2066
16. Maggi L, Salerno F, Bragato C et al (2013) Familial adult-onset Pompe disease associated with unusual clinical and histological features. Acta Myol 32:v85–v90
17. Martini C, Ciana G, Benettoni A et al (2001) Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology 57:906–908
18. McDowell R, Li JS, Benjamin DK et al (2008) Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. Genet Med 10:758–762
19. McNamara ER, Austin S, Case L, Wiener JS, Peterson AC, Kishnani PS (2015) Expanding our understanding of lower urinary tract symptoms and incontinence in adults with Pompe disease. JIMD Rep [Epub ahead of print]
20. Nakamura Y, Tanimura A, Yasuoka C, Kato H (1979) An autopsy case of type II glycogenosis. Kurume Med J 26:349–354
21. Patel TT, Banugaria SG, Frush DP, Enterline DS, Tanpaiboon P, Kishnani PS (2013) Basilar artery aneurysm: a new finding in classic infantile Pompe disease. Muscle Nerve 47:613–615
22. Prakalapakorn SG, Proia AD, Yanovitch TL et al (2014) Ocular and histologic findings in a series of children with infantile Pompe disease treated with enzyme replacement therapy. J Pediatr Ophthalmol Strabismus 20:1–8
23. Prater SN, Banugaria SG, DeArmey SM et al (2012) The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 14:800–810
24. Quenardelle V, Bataillard M, Bazin D, Lannes B, Wolff V, Echaniz-Laguna A (2014) Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infracts. J Neurol 262:473–475
25. Remiche G, Herbaut AG, Ronchi D et al (2012) Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition. Eur Neurol 68:75–78
26. Rohrbach M, Klein A, Kohli-Wiesner A et al (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33:751–757
27. Sacconi S, Bocquet JD, Chanalet S, Tanant V, Salviati L, Desnuelle C (2010) Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J Neurol 257:1730–1733
28. Sakurai I, Tosaka A, Mori Y, Imura S, Aoki K (1974) Glycogenosis type II (Pompe) – the fourth autopsy case in Japan. Acta Pathologica Japonica 24:829–846
29. Sidman RL, Taksir T, Fidler J et al (2008) Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol 67:803–818
30. Spiridigliozzi GA, Heller JH, Kishnani PS (2012) Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow up. Am J Med Genet Part C 160C:22–29
31. Stocker JT, Dehner LP (eds) (2001) Pediatric pathology, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp. 1444–1446, p. 1451
32. Tan QK, Cheah SM, DeArmey SM, Kishnani PS (2013) Low anal sphincter tone in infantile-onset Pompe disease: an emerging clinical issue in enzyme replacement therapy patients requiring special attention. Mol Genet Metab 108:142–144
33. Temple JK, Dunn DW, Blitzer MG, Shapira E (1985) The “muscular variant” of Pompe disease: clinical, biochemical and histologic characteristics. Am J Med Genet 21:597–604
34. Teng Y-T, Su W-J, Hou J-W, Huang S-F (2004) Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 27:379–384
35. Thurberg BL, Lynch Maloney C, Vaccaro C et al (2006) Characterization of pre-and post-treatment pathology after enzyme replacement therapy for Pompe disase. Lab Invest 86: 1208–1220
36. Yanovitch TL, Banugaria SG, Proia AD, Kishnani PS (2010) Clinical and histologic ocular findings in Pompe disease. J Pediatr Ophthalmol Strabismus 47:34–40
37. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT (2000) Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356:397–398